KR940018086A - 나노캡슐을 함유하는 제약조성물 - Google Patents

나노캡슐을 함유하는 제약조성물 Download PDF

Info

Publication number
KR940018086A
KR940018086A KR1019940000574A KR19940000574A KR940018086A KR 940018086 A KR940018086 A KR 940018086A KR 1019940000574 A KR1019940000574 A KR 1019940000574A KR 19940000574 A KR19940000574 A KR 19940000574A KR 940018086 A KR940018086 A KR 940018086A
Authority
KR
South Korea
Prior art keywords
surfactant
pharmaceutical composition
aqueous phase
oil
phase
Prior art date
Application number
KR1019940000574A
Other languages
English (en)
Other versions
KR100311056B1 (ko
Inventor
브랭크스 앙리
드모스티어 마르탱
드리어스 미쉘
Original Assignee
알.뒤셀도르프, 아이.씨.아이.에이.
유씨비 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알.뒤셀도르프, 아이.씨.아이.에이., 유씨비 에스.에이. filed Critical 알.뒤셀도르프, 아이.씨.아이.에이.
Publication of KR940018086A publication Critical patent/KR940018086A/ko
Application granted granted Critical
Publication of KR100311056B1 publication Critical patent/KR100311056B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/14—Polymerisation; cross-linking
    • B01J13/18—In situ polymerisation with all reactants being present in the same phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 나노캡슐(nanocapsule)로 이루어진 콜로이드 현탁액 형태의 제약 조성물 및 이 조성물의 제조방법에 관한 것으로서, 본 발명의 조성물은, 계면활성제가 용해된 상태로 함유되어 있고 직경이 500nm이하인 다수개의 나노캡슐이 분산되어 있는 상태인 오일을 필수적으로 포함하고 있으며, 상기의 나노캡슐에는 치료적 활성물질, 계면활성제 및 선택적으로 에탄올의 용액 또는 현탄액을 필수로 하여 구성된 수성상이 들어있다. 상기 나노캡슐의 벽은 폴리(알킬 2-시아노아크릴레이트)로 형성되는데, 상기 화합물의 알킬 라디칼은 1개 내지 6개의 탄소원자로 이루어져 있다. 본 발명의 조성물은 폴리펩티드와 폴리삭카라이드의 구강투여용으로 특히 적합하다.

Description

나노캡슐을 함유하는 제약조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 나노캡슐의 콜로이드 현탁액 형태인 제약 조성물로서, 계면활성제가 용해된 상태로 함유되어 있고 직경이 50nm 미만인 다수개의 나노캡슐들이 현탁되어 있으며, 사익 나노캡슐내에는 물에 치료적 활성 물질과 계면활성제가 함유된 용액 또는 현탁액으로 이루어진 pH1 내지 7의 수성상이 포함되어 있어서 상기 나노캡슐의 벽이 폴리(알킬 2-시아노아크릴산염)으로 형성되며 이때의 알킬 라디칼은 탄소원자가 1개 내지 6개인 것을 특징으로 하는 제약 조성물.
  2. 제 1 항에 있어서, 치료적 활성물질이 폴리펩티드 또는 폴리삭카라이드인 것을 특징으로 하는 제약 조성물.
  3. 제 1 항에 있어서, 치료적 활성물질이 칼시토닌, 소마토스타틴, 인슐린 또는 헤파린인 것을 특징으로 하는 제약 조성물.
  4. 제 1 항에 있어서, 수성상에 수성상 ml당 100μ1 내지 1,000μ1의 에탄올이 더 포함되는 것을 특징으로 하는 제약 조성물.
  5. 제 4 항에 있어서, 수성상에 ml당 200μ1 내지 500μ1의 에탄올이 포함되어 있는 것을 특징으로 하는 제약 조성물.
  6. 제 1 항에 있어서, 오일이 식물성 오일, 광물성 오일, 또는 벤질 벤조산염 및 고급 지방산의 글리세리드로부터 선택된 유성 화합물인 것을 특징으로 하는 제약 조성물.
  7. 제 1 항에 있어서, 유성상에 대한 수성상의 부피가 1:100 내지 20:100인 것을 특징으로 하는 제약 조성물.
  8. 제 7 항에 있어서, 유성상에 대한 수성상의 부피비가 5:100 내지 15:100인 것을 특징으로 하는 제약 조성물.
  9. 제 1 항에 있어서, 수성상내의 계면활성제가 라우릴황산나트륨, 디옥틸술포숙신산나트륨, 폴리옥시에틸렌 소르비탄 지방산 에스테르, 또는 산화에틸렌 및 프로필렌글리콜이나 폴리옥시에틸렌글리콜의 혼합유도체로 이루어진 군으로부터 선택되는 것을 특징으로 하는 제약 조성물.
  10. 제 1 항에 있어서, 수성상내의 계면활성제의 농도가 수성상 부피당 0.1 내지 10%(w/v)의 계면활성제인 것을 특징으로 하는 제약 조성물.
  11. 제 1 항에 있어서, 유성상내의 계면활성제가 소르비탄 지방산 에스테르 및 담즙산의 가용성 염으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 제약 조성물.
  12. 제 1 항에 있어서, 유성상내의 계면활성제의 농도가 유성상 부피당 0.1 내지 20%(w/v) 사이인 것을 특징으로 하는 제약 조성물.
  13. 제 1 항에 따른 제약 조성물의 제조방법으로서, a)치료적 활성물질 및 계면활성제가 물에 들어 있고 pH가 1 내지 7인 용액 또는 현탁액으로 이루어진 수성상을 제조하는 단계; b)상기 수성상을 서서히 휘저으면서 오일 및 이 오일에 용해된 계면활성제로 이루어진 유성상에 조금씩 첨가하여 오일내의 물(water-in-oil) 유형의 유탁액을 형성시키는 단계; 및 c)상기 오일내의 물 유형의 유탁액을 저으면서 여기에 용매부재하에 1가지 이상의 알킬 2-시아노아크릴레이트···여기에서 알킬라디칼은 1개 내지 6개의 탄소원자를 가진다···를 첨가하여, 첨가된 알킬 2-시아노아크릴레이트를 중합시키기에 충분한 시간동안 알킬 2-시아노아크릴레이트가 실온에서 중합되게 하고, 직경이 500nm 이하이고 상기의 수성상을 포함하고 있는 나노캡슐의 유성상내 현탁액을 공정 생성물로서 회수하는 단계로 이루어지는 것을 특징으로 하는 제약 조성물의 제조방법.
  14. 제13항에 있어서, 알킬 2-시아노아크릴산염의 중합반응을 3 내지 8시간동안 수행하는 것을 특징으로 하는 제약 조성물의 제조방법.
  15. 제13항에 있어서, 치료적 활성물질이 칼시토닌, 소마토스타틴, 인슐린 또는 헤파린인 것을 특징으로 하는 제약 조성물의 제조방법.
  16. 제13항에 있어서, 수성상에 수성상 ml당 100μ1 내지 1,000μ1의 에탄올이 더 포함되는 것을 특징으로 하는 제약 조성물의 제조방법.
  17. 제13항에 있어서, 수성상내의 계면활성제가 라우릴황산나트륨인 것을 특징으로 하는 제약 조성물의 제조방법.
  18. 제13항에 있어서, 수성상내의 계면활성제의 농도가 수성상 부피당 0.1 내지 10%(w/v)의 계면활성제인 것을 특징으로 하는 제약 조성물의 제조방법.
  19. 제13항에 있어서, 유성상내의 계면활성제가 소르비탄 모노-올레산염인 것을 특징으로 하는 제약 조성물의 제조방법.
  20. 제13항에 있어서, 유성상내의 계면활성제의 농도가 유성상 부피당 0.1 내지 20%(w/v) 사이인 것을 특징으로 하는 제약 조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940000574A 1993-01-18 1994-01-14 나노캡슐을함유하는약제조성물 KR100311056B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9300875.3 1993-01-18
GB939300875A GB9300875D0 (en) 1993-01-18 1993-01-18 Nanocapsule containing pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR940018086A true KR940018086A (ko) 1994-08-16
KR100311056B1 KR100311056B1 (ko) 2002-03-21

Family

ID=10728864

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940000574A KR100311056B1 (ko) 1993-01-18 1994-01-14 나노캡슐을함유하는약제조성물

Country Status (21)

Country Link
US (1) US5500224A (ko)
EP (1) EP0608207B1 (ko)
JP (1) JP3688731B2 (ko)
KR (1) KR100311056B1 (ko)
AT (1) ATE172111T1 (ko)
AU (1) AU670840B2 (ko)
CA (1) CA2113243C (ko)
CY (1) CY2132B1 (ko)
DE (1) DE69413857T2 (ko)
DK (1) DK0608207T3 (ko)
ES (1) ES2122217T3 (ko)
FI (1) FI111441B (ko)
GB (1) GB9300875D0 (ko)
HU (1) HUT67213A (ko)
NO (1) NO307445B1 (ko)
NZ (1) NZ250673A (ko)
PL (1) PL173254B1 (ko)
RU (1) RU2145498C1 (ko)
SG (1) SG43682A1 (ko)
TW (1) TW336174B (ko)
ZA (1) ZA94205B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100487083B1 (ko) * 2001-05-09 2005-05-03 주식회사 메디프렉스 양친성 헤파린 유도체의 점막 흡수를 증가시키기 위한제조방법

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721510B1 (fr) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
EP0808154B1 (en) * 1995-02-06 2000-12-20 Elan Pharma International Limited Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
JP3759986B2 (ja) * 1995-12-07 2006-03-29 フロイント産業株式会社 シームレスカプセルおよびその製造方法
FR2766368B1 (fr) * 1997-07-24 2000-03-31 Univ Claude Bernard Lyon Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU4724401A (en) * 2000-02-28 2001-09-12 Genesegues Inc Nanocapsule encapsulation system and method
FR2806005B1 (fr) * 2000-03-10 2002-06-14 Univ Claude Bernard Lyon Procede de preparation de particules colloidales sous forme de nanocapsules
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
ATE424815T1 (de) * 2001-12-03 2009-03-15 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
KR20050038005A (ko) 2002-07-18 2005-04-25 헬릭스 바이오파마 코포레이션 암세포 성장의 저해를 위한 우레아제의 사용
US20060189554A1 (en) * 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2006035417A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
FR2899800B1 (fr) * 2006-04-13 2008-10-10 Oreal Emulsion eau dans l'huile pour le traitement des fibres keratiniques comprenant un monomere cyanoacrylate
FR2899797A1 (fr) * 2006-04-13 2007-10-19 Oreal Emulsion eau dans l'huile pour le traitement des fibres keratiniques comprenant un monomere cyanoacrylate et de l'ammoniaque
ES2400964T3 (es) 2007-04-04 2013-04-15 Sigmoid Pharma Limited Composiciones famacéuticas de ciclosporina
WO2008132707A1 (en) * 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
JP2010526054A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド 併用医薬組成物
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
WO2009135855A2 (en) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation of biologically active agents
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CN102470106B (zh) 2009-05-18 2015-09-23 希格默伊德药业有限公司 包含油滴的组合物
IN2012DN00781A (ko) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
RU2566069C2 (ru) * 2013-05-31 2015-10-20 Общество с ограниченной ответственностью "Изварино Фарма" Система доставки вещества белковой природы в виде наночастиц и способ ее получения
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
SG11201609954VA (en) * 2014-05-30 2016-12-29 Abbvie Deutschland Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
ES2858517T3 (es) 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Composiciones que comprenden ciclosporina
BR112017015582A2 (pt) 2015-01-23 2018-03-13 Helix Biopharma Corp conjugados de anticorpo-urease para propósitos terapêuticos
RU2590651C1 (ru) * 2015-03-30 2016-07-10 Александр Александрович Кролевец Способ получения нанокапсул рибофлавина в геллановой камеди
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY
WO2023089240A1 (en) * 2021-11-19 2023-05-25 Nanoform Finland Oyj A composition comprising nanosized active pharmaceutical ingredient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515960A1 (fr) * 1981-11-06 1983-05-13 Alkhouri Fallouh Nazir Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application
JPS6061521A (ja) * 1983-09-16 1985-04-09 Kyowa Hakko Kogyo Co Ltd マイクロカプセル化製剤
DE3341001A1 (de) * 1983-11-12 1985-05-23 Krause, Hans Jürgen Nanopartikel aus bioabbaubarem, synthetischem material, verfahren zu deren herstellung und ihre anwendung
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100487083B1 (ko) * 2001-05-09 2005-05-03 주식회사 메디프렉스 양친성 헤파린 유도체의 점막 흡수를 증가시키기 위한제조방법

Also Published As

Publication number Publication date
FI940115A (fi) 1994-07-19
NO940111D0 (no) 1994-01-12
EP0608207B1 (fr) 1998-10-14
CY2132B1 (en) 2002-06-21
FI940115A0 (fi) 1994-01-11
CA2113243A1 (en) 1994-07-19
AU670840B2 (en) 1996-08-01
NO940111L (no) 1994-07-19
HU9400107D0 (en) 1994-05-30
PL301841A1 (en) 1994-07-25
RU94002474A (ru) 1996-11-10
TW336174B (en) 1998-07-11
CA2113243C (en) 2008-08-05
KR100311056B1 (ko) 2002-03-21
NZ250673A (en) 1994-11-25
DE69413857D1 (de) 1998-11-19
ES2122217T3 (es) 1998-12-16
FI111441B (fi) 2003-07-31
PL173254B1 (pl) 1998-02-27
US5500224A (en) 1996-03-19
DE69413857T2 (de) 1999-04-15
JP3688731B2 (ja) 2005-08-31
GB9300875D0 (en) 1993-03-10
EP0608207A1 (fr) 1994-07-27
AU5309794A (en) 1994-07-21
ZA94205B (en) 1994-08-22
RU2145498C1 (ru) 2000-02-20
ATE172111T1 (de) 1998-10-15
NO307445B1 (no) 2000-04-10
HUT67213A (en) 1995-03-28
DK0608207T3 (da) 1999-06-23
JPH06256172A (ja) 1994-09-13
SG43682A1 (en) 1997-11-14

Similar Documents

Publication Publication Date Title
KR940018086A (ko) 나노캡슐을 함유하는 제약조성물
US4411893A (en) Topical medicament preparations
AU752466B2 (en) Stabilized ascorbic acid, composition, and method of use
KR970032845A (ko) O/w/o형 복합 에멀젼 및 그 제조방법
KR900000071A (ko) 고농도의 향로를 갖는 연속적 수성상의 향수 조성물
Capuzzi et al. Mixtures of stearoyl-6-O-ascorbic acid and α-tocopherol: a monolayer study at the gas/water interface
Chambers et al. The effect of parathyroid hormone, 1, 25‐dihydroxycholecalciferol and prostaglandins on the cytoplasmic activity of isolated osteoclastsxs
KR950015063B1 (ko) 함수성 외용제
JPH0812568A (ja) 化粧料
JPS61289034A (ja) イソカルバサイクリン類脂肪乳剤
KR900018027A (ko) 피페리딘 유도체, 그의 제조 방법, 및 그것을 유효성분으로 함유하는 의약용 조성물
KR910000713A (ko) 크로만 유도체
JPS58206597A (ja) 水性燐脂質溶液
DE60012068D1 (de) Zusammensetzung mit kontinuierlicher wässeriger Phase, die L-2-Oxothiazolidin- 4-carbonsäure enthält".
US3170836A (en) Injectable compositions comprising a copper-containing chelate complex compound dispersed in a stabilized oil-in-water emulsion and method of using the same
TH13421B (th) สารผสมทางเภสัชกรรมที่มีนาโนแคปซูลเป็นองค์ประกอบ
TH16339A (th) สารผสมทางเภสัชกรรมที่มีนาโนแคปซูลเป็นองค์ประกอบ
EP0121856A2 (de) Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung
JPS62161724A (ja) ３―オキシゲルミルプロピオン酸を有効成分とする外用剤
CS252559B1 (en) Polymer stabilizer of emulsion type water in oil
JPH05252895A (ja) にんにく成分包接化合物強壮剤
US3471617A (en) Pharmaceutical compositions of ammoniated mercury salicylate and methods for their use
JPH04342530A (ja) ７−フルオロプロスタサイクリン類脂肪乳剤
EP0330665A1 (en) Hydrosoluble ubidecarenones derivatives and their preparation
JP2003252799A (ja) 脂溶性パラオキシ安息香酸類の溶解補助剤、溶液および用途

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080911

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee